Patents by Inventor Jin Zeng

Jin Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051365
    Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS GD12 and/or other G12 mutants.
    Type: Application
    Filed: September 20, 2024
    Publication date: February 13, 2025
    Inventors: Hong LIN, Juan LUENGO, Audrey HOSPITAL, Jin ZENG, Pei GAN
  • Patent number: 12145947
    Abstract: Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: November 19, 2024
    Assignee: QUANTA THERAPEUTICS, INC.
    Inventors: Hong Lin, Juan Luengo, Neil Johnson, Audrey Hospital, Jin Zeng
  • Publication number: 20240199650
    Abstract: Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.
    Type: Application
    Filed: November 7, 2023
    Publication date: June 20, 2024
    Inventors: Hong LIN, Juan LUENGO, Neil JOHNSON, Audrey HOSPITAL, Jin ZENG
  • Publication number: 20230223156
    Abstract: The present disclosure provides a consistency evaluation method for a traditional extraction process and a modern extraction process of a traditional Chinese medicine (TCM) compound preparation. In the present disclosure, the reference correlation degree is calculated based on the relative deviation. The reference correlation degree is within a threshold interval of [??, 1]. If the relative deviation is 0, the reference correlation degree is 100%, and at the moment, the quality of a modern extraction sample is completely consistent with that of a reference sample. Thus, compared with the relative deviation, the reference correlation degree can represent a quality difference between the modern extraction sample and the reference sample more intuitively and clearly.
    Type: Application
    Filed: November 15, 2022
    Publication date: July 13, 2023
    Applicant: SICHUAN ACADEMY OF CHINESE MEDICINE SCIENCES
    Inventors: Aijun ZHANG, Junning ZHAO, Shan DAI, Shuai LI, Hongmei ZHU, Jin ZENG, Jiuzhou MAO
  • Patent number: 11459361
    Abstract: The application relates to a sericin protein particle with an oxidative stress property, a method for preparing the same and use thereof. The particle is formed by sericin protein and a tellurium compound. In the method for preparing the sericin protein particle, bis(1-hydroxydodecyl) telluride is first prepared and then mixed with a solution of sericin protein, and a resulting solution is agitated continuously for some time to obtain telluride-modified sericin protein. Then, the solution of the sericin protein is added dropwise into absolute ethanol to obtain a precipitated product. An aqueous solution of the precipitated product and a solution of magnesium ions are mixed and agitated for a certain time to obtain the sericin protein particle with an oxidative stress property. The sericin protein particle disclosed is a hollow particle having a diameter in a range of 600-1250 nm, and is capable of loading biomacromolecule drugs or other components.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 4, 2022
    Assignee: Hangzhou Singclean Medical Products Co., Ltd
    Inventors: Wei Huang, Zhong Wang, Jin Zeng, Yurong Cai
  • Publication number: 20220081492
    Abstract: Provided are a chitin whisker-enhanced hyaluronic acid cell scaffold and a preparation method thereof. Components of the cell scaffold include chitin whiskers and cross-linked hyaluronic acid. The chitin whisker-enhanced hyaluronic acid cell scaffold is obtained by dispersing chitin whiskers into deionized water using ultrasound, followed by addition of hyaluronic acid and uniform mixing to obtain an aqueous solution, adjusting a pH value of the aqueous solution to be in a range of 4.0 to 6.0, subjecting the aqueous solution to a cross-linking reaction, dialyzing a reaction product in a phosphate buffer solution, and freeze drying a resulting product. The chitin whisker-enhanced hyaluronic acid cell scaffold and the preparation method thereof can increase a mechanical property and a resistance to degradation of a scaffold material and expand an application scope of hyaluronic acid cell scaffolds.
    Type: Application
    Filed: November 30, 2020
    Publication date: March 17, 2022
    Inventors: Feifei Wu, Jie Li, Jin Zeng, Caili Ma, Kui Zhou, Shitu Ma
  • Patent number: 11098168
    Abstract: Related to is the field of polymer materials, and particularly related to are a method for preparing cross-linked hyaluronic acid gel and a cross-linked hyaluronic acid gel prepared by the method. Under an alkaline condition, a disulfide cross-linking agent is dropwise added into an alkaline solution of hyaluronic acid for cross-linking reaction, and after the reaction is completed, dialysis and freeze drying are carried out to obtain the cross-linked hyaluronic acid gel. A new disulfide cross-linking agent N,N-bis(acroloyl)cystamine is introduced, and it effectively solves degradation regulating problems of cross-linked hyaluronic acid; the disulfide bond ratio is controllable, which can effectively improve a cross-linking modification degree ratio in the cross-linked hyaluronic acid, thereby solving the problem of difficult degradation of highly cross-linked hyaluronic acid gel in the past. The cross-linked material has potential applications in aspects of drug carriers and tissue engineering scaffolds.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 24, 2021
    Assignee: Hangzhou Singclean Medical Products Co., Ltd.
    Inventors: Jin Zeng, Weiwei Wang, Weiqing Sun
  • Publication number: 20210154363
    Abstract: The present disclosure provides a preparation method of a collagen melanocyte complex and use of the collagen melanocyte complex. The collagen material is a scaffold material with good biocompatibility, mechanical properties, and degradation performance, which is prepared based on tissue engineering technology. The present disclosure relates to the preparation of a collagen scaffold and the construction of a collagen melanocyte complex. Melanocytes on the scaffold material have higher cell activity and better melanin secretion ability. The collagen melanocyte complex avoids the loss of cell suspension during cell transplantation and provides a good three-dimensional growth environment for cells. The collagen melanocyte complex prepared by the present disclosure can be used in patients with vitiligo or patients with pigment deficiency and epidermal damage.
    Type: Application
    Filed: March 30, 2020
    Publication date: May 27, 2021
    Inventors: Jin Zeng, Caili Ma, Weiqing Sun, Wei Huang
  • Publication number: 20210107954
    Abstract: The application relates to a sericin protein particle with an oxidative stress property, a method for preparing the same and use thereof. The particle is formed by sericin protein and a tellurium compound. In the method for preparing the sericin protein particle, bis(1-hydroxydodecyl) telluride is first prepared and then mixed with a solution of sericin protein, and a resulting solution is agitated continuously for some time to obtain telluride-modified sericin protein. Then, the solution of the sericin protein is added dropwise into absolute ethanol to obtain a precipitated product. An aqueous solution of the precipitated product and a solution of magnesium ions are mixed and agitated for a certain time to obtain the sericin protein particle with an oxidative stress property. The sericin protein particle disclosed is a hollow particle having a diameter in a range of 600-1250 nm, and is capable of loading biomacromolecule drugs or other components.
    Type: Application
    Filed: June 30, 2020
    Publication date: April 15, 2021
    Inventors: Wei Huang, Zhong Wang, Jin Zeng, Yurong Cai
  • Patent number: 10865256
    Abstract: Disclosed is a method for preparing cross-linked hyaluronic acid-based cell scaffold material. The hyaluronic acid-based cell scaffold is obtained by subjecting a hyaluronic acid and a disulfide cross-linking agent to an amidation reaction, followed by dialysis-freeze drying. The cell scaffold has abundant pores, good mechanical strength which ensures that the scaffold does not rupture in transplantation, and good biocompatibility. The method is advantageous in that the raw material is easy to obtain, the reaction condition is moderate, and the process is simple. Cross-linked networks of the prepared hydrogel contain disulfide bonds, which can quickly split into single chains at the presence of small molecular glutathione. The hyaluronic acid-based cell scaffold has flexibly controllable mechanical property, disaggregation ability, and swelling property, and therefore has wide applications in facilitating cartilage injury repair, skin repair, cell culture, etc.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 15, 2020
    Assignee: Hangzhou Singclean Medical Products Co., Ltd.
    Inventors: Jin Zeng, Weiqing Sun
  • Patent number: 10711950
    Abstract: A light bulb base includes a cylinder-shaped insulating component, a cylinder-shaped base connector, a metal thimble and a heat-dissipating component. The insulating component has a jack at its first side. The base connector has a circumferential interior bore extending there through. The interior bore accommodates the insulating component at a first side of the base connector. The metal thimble inserts into the jack at its first side via the interior bore. Such that the metal thimble rivets the base connector to the insulating component. The heat-dissipating component has a first side coupled to a second side of the insulating component. The heat-dissipating component includes a first opening at its second side. The heat-dissipating component also includes a cavity chamber disposed inside the first opening.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: July 14, 2020
    Assignee: XIAMEN ECO LIGHTING CO. LTD.
    Inventors: Mao Jin Zeng, Liang Liang Cao, Xiao Bo Chen
  • Publication number: 20200095383
    Abstract: Related to is the field of polymer materials, and particularly related to are a method for preparing cross-linked hyaluronic acid gel and a cross-linked hyaluronic acid gel prepared by the method. Under an alkaline condition, a disulfide cross-linking agent is dropwise added into an alkaline solution of hyaluronic acid for cross-linking reaction, and after the reaction is completed, dialysis and freeze drying are carried out to obtain the cross-linked hyaluronic acid gel. A new disulfide cross-linking agent N,N-bis(acroloyl)cystamine is introduced, and it effectively solves degradation regulating problems of cross-linked hyaluronic acid; the disulfide bond ratio is controllable, which can effectively improve a cross-linking modification degree ratio in the cross-linked hyaluronic acid, thereby solving the problem of difficult degradation of highly cross-linked hyaluronic acid gel in the past. The cross-linked material has potential applications in aspects of drug carriers and tissue engineering scaffolds.
    Type: Application
    Filed: June 27, 2019
    Publication date: March 26, 2020
    Inventors: Jin Zeng, Weiwei Wang, Weiqing Sun
  • Publication number: 20190270829
    Abstract: Disclosed is a method for preparing cross-linked hyaluronic acid-based cell scaffold material. The hyaluronic acid-based cell scaffold is obtained by subjecting a hyaluronic acid and a disulfide cross-linking agent to an amidation reaction, followed by dialysis-freeze drying. The cell scaffold has abundant pores, good mechanical strength which ensures that the scaffold does not rupture in transplantation, and good biocompatibility. The method is advantageous in that the raw material is easy to obtain, the reaction condition is moderate, and the process is simple. Cross-linked networks of the prepared hydrogel contain disulfide bonds, which can quickly split into single chains at the presence of small molecular glutathione. The hyaluronic acid-based cell scaffold has flexibly controllable mechanical property, disaggregation ability, and swelling property, and therefore has wide applications in facilitating cartilage injury repair, skin repair, cell culture, etc.
    Type: Application
    Filed: March 1, 2019
    Publication date: September 5, 2019
    Inventors: Jin Zeng, Weiqing Sun
  • Publication number: 20180280392
    Abstract: Disclosed is a pharmaceutical preparation having 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine-1-yl-pyridine-2-yl amino group)-8H-pyrido[2,3-d]pyrimidine-7-one or salt thereof as an active ingredient, the salt comprising hydrochloride or isethionate, and the dosage form thereof comprising tablets and capsules both having good stability and excellent dissolution performance.
    Type: Application
    Filed: November 6, 2015
    Publication date: October 4, 2018
    Inventors: Jin ZENG, Ruijun WANG, Xiaolei WANG
  • Patent number: 8410095
    Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Hong Lin, Juan I. Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
  • Publication number: 20120053147
    Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K}, PI3K?, and/or PI3K?.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 1, 2012
    Inventors: Hong Lin, Juan I Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
  • Patent number: 5525471
    Abstract: A method for subtractive hybridization of desired DNA sequences from two cell or tissue populations. cDNA from experimental cells or tissues is modified by incorporation of nucleoside analogs to prevent subsequent exonuclease attack. Hybridization of the experimental and control cDNA is performed using the phenol-emulsion reassociation technique. The hybridized DNA is incubated with exonucleases, resulting in degradation of all but the desired duplex DNA which may then be amplified. This technique may be used to isolate differentially expressed genes or gene fragments and will contribute to our understanding of pathological conditions and developmental regulation.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: June 11, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Jin Zeng